Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome Signature Post Reovirus Treatment In KRAS Mutated Colorectal Cancer

ABSTRACT: Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 45-50% of CRC patients possess KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patient samples possessing KRAS mutated metastatic CRC. This is the raw data from the peripheral mononuclear cell (PBMC) samples at 4 timepoints (pre treatment, 48 hours, day 8, and day 15).

ORGANISM(S): Homo sapiens

PROVIDER: GSE173636 | GEO | 2021/05/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcriptome Signature Post Reovirus Treatment In KRAS Mutated Colorectal Cancer

Project description:Transcriptome Signature Post Reovirus Treatment In KRAS Mutated Colorectal Cancer

| PRJNA726514 | ENA

Microarray analysis of human NK cells following oncolytic reovirus treatment of peripheral blood mononuclear cells (PBMC)

Project description:Oncolytic viruses (OV) kill tumour cells directly and induce anti-tumour immunity. We analysed gene expression profiles in human NK cells following treatment of PBMC with oncolytic reovirus in vitro.

2022-01-03 | E-MTAB-9826 | biostudies-arrayexpress

Reshaping of the MHC-I ligandome in response to reovirus-based cancer immunotherapy

Project description:Oncolytic viruses (OVs), known for their cancer-killing characteristics, overturn tumor-associated defects in antigen presentation through the MHC class I pathway and induce protective neo antitumor CD8 T cell responses. Nonetheless, whether OVs shape the tumor MHC-I ligandome remains unknown. Here, we investigated if an OV induces the presentation of novel MHC I-bound tumor antigens (termed tumor MHC-I ligands). Using comparative mass spectrometry (MS)-based MHC-I ligandomics, we determined differential tumor MHC-I ligand expression following treatment with oncolytic reovirus in a murine ovarian cancer model. In vitro we found that reovirus induces the presentation of tumor MHC-I ligands in cancer cells. Concurrent multiplexed quantitative proteomics revealed that the changes in tumor MHC-I ligand presentation were mostly independent of reovirus-induced alterations of their source proteins. In an in vivo model, tumor MHC-I ligands were induced by reovirus in tumors but also, more importantly, analysis of spleens (a source of antigen-presenting cells) showed exclusive induction of most MHC-I ligands occurred in tumor-bearing mice. Finally, IFNγ assays demonstrated immunogenicity of the reovirus-induced MHC-I ligands. OV-induced MHC-I responses may be exploited in combinatorial approaches to promote the efficacy of cancer immunotherapies.

2019-05-20 | PXD013066 | Pride

Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF and M-CSF-Differentiated Bone Marrow-Derived Cells

Project description:To explore reovirus-macrophage interactions, we performed tandem mass tag (TMT)-based quantitative temporal proteomics on mouse bone marrow-derived macrophages (BMMs) generated with 2 cytokines, M-CSF and GM-CSF, representing anti- and pro-inflammatory macrophages, respectively. We quantified 6,863 proteins across five time points in duplicate, comparing M-CSF (M-BMM) and GM-CSF (GM-BMM) in response to OV. We find that GM-BMMs have lower expression of key intrinsic proteins that facilitate an anti-viral immune response, express higher levels of reovirus receptor protein JAM-A and are more susceptible to oncolytic reovirus infection compared to M-BMMs. Interestingly, although M-BMMs are less susceptible to reovirus infection and subsequent cell death, they initiate an anti-reovirus adaptive T cell immune response comparable to that of GM-BMMs. Taken together, these data describe distinct proteome differences between these two macrophage populations in terms of their ability to mount anti-viral immune responses.

2020-01-07 | PXD015203 | Pride

Reovirus low-density particles package viral and cellular RNA

Project description:Packaging of segmented, double-stranded RNA viral genomes requires coordination of multiple viral proteins and RNA segments. For mammalian orthoreovirus (reovirus), evidence suggests either all ten or zero viral RNA segments are simultaneously packaged in a highly coordinated process hypothesized to exclude host RNA. Accordingly, reovirus generates genome-containing virions and “genomeless” top component particles. However, despite ostensibly lacking the genome, top component particles maintain a low level of infectivity. Whether reovirus particles can package host RNA is unknown. To gain insight into reovirus packaging potential and mechanisms, we employed next-generation RNA-sequencing to define the viral and host RNA content of purified reovirus virions and top component particles. Reovirus top component particles contained double-stranded viral RNA segments in similar proportions but at reduced levels compared to virions. Top component particles also were enriched for numerous host RNAs, especially short, non-polyadenylated transcripts, that differed by reovirus strain, independent of the viral polymerase. In contrast, virions were enriched for very few host RNAs. Collectively, these findings indicate that genome packaging into reovirus virions is exquisitely selective, while incorporation of host RNAs into top component particles is more promiscuous or differentially selective and may contribute to or result from inefficient viral RNA packaging.

2021-06-08 | GSE164270 | GEO

High-resolution spatial transcriptomics of myocarditic heart from reovirus-infected neonatal mice

Project description:A significant fraction of sudden death in young adults is due to myocarditis, an inflammatory disease of the heart, most often caused by viral infection. Here we used high resolution spatially RNA sequencing using Slide-seq platform to study cellular phenotypes in a myocarditic heart from reovirus-infected neonatal mice at day 7 post infection. Our measurements give insight into the cardiac cell-type specific spatially-restricted inflammatory and stress responses in the myocarditic heart. Overall, our data identify spatially restricted cellular interactions and cell-type specific host responses during reovirus-induced myocarditis.

2022-08-14 | GSE211096 | GEO

Expresssion data from reovirus treated breast cancer cell lines

Project description:Reovirus mediated cell death of breast cancer is orchestrated via apoptotic cell death pathways We used inhouse microarrays to detail the global programme of gene expression following reovirus treatment

2015-06-13 | GSE69813 | GEO

Expression data from tumors generated from genome-engineered mice

Project description:Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 30–40% of human colorectal cancers (CRC). However, specific therapeutics against KRAS-mutated CRC have not been established. We have previously reported mouse models for colon cancer with and without Kras mutations (CDX2P-G22Cre;Apcflox/flox; KrasG12D and CDX2P-G22Cre;Apcflox/flox mice, respectively). Herein, we aimed to identify candidate genes as novel therapeutic targets or biomarkers for KRAS-mutated CRC by comparing the gene expression profiles of these two mouse models.

2015-12-25 | GSE75435 | GEO

Mutated in Colorectal Cancer (MCC): A Novel Centrosomal Protein Involved in Intestinal Homeostasis and Disease

Project description:Mutated in Colorectal Cancer (MCC) is a candidate tumor suppressor gene reported to be somatically mutated in the inherited colorectal cancer (CRC) syndrome Familial Adenomatous Polyposis. Additionally, MCC deletion and loss-ofheterozygosity have also been reported as a common event in human CRC. However,to date, more than 28 years since its discovery, the mechanisms by which MCC contributes to intestinal cancer development as well as its function during normal intestinal tissue homeostasis remain unknown.

2023-07-29 | PXD035614 | JPOST Repository

Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models [LLC RNA-seq]

Project description:KRAS mutation is a common driver in solid tumors, and KRAS-mutated tumors are relatively resistant to radiotherapy. Therefore, we investigated the combined effect of radiation and KRAS-MEK inhibitors (AMG510 and trametinib) in KRAS-mutated tumors.

2022-10-01 | GSE209766 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data